{"transactions":[{"id":733662,"issuer":{"id":6051,"kind":"organization","name":"Alector, Inc.","symbol":"ALEC"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-17T20:05:07.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":9450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders."}],"balance_after":9450,"derivative":{"exercise_price":0,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":9450},"source":{"system":"sec-edgar","filing":"0001193125-26-274123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1213895/000119312526274123/ownership.xml","form_type":"4"}},{"id":733661,"issuer":{"id":6051,"kind":"organization","name":"Alector, Inc.","symbol":"ALEC"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:05:07.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":28700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":98650,"source":{"system":"sec-edgar","filing":"0001193125-26-274123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213895/000119312526274123/ownership.xml","form_type":"4"}},{"id":1113054,"issuer":{"id":6051,"kind":"organization","name":"Alector, Inc.","symbol":"ALEC"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T22:05:05.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":9450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in 12 equal monthly installments beginning on July 11, 2025, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders."}],"balance_after":9450,"derivative":{"exercise_price":1.63,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":9450},"source":{"system":"sec-edgar","filing":"0000950170-25-085615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1213895/000095017025085615/ownership.xml","form_type":"4"}},{"id":1113053,"issuer":{"id":6051,"kind":"organization","name":"Alector, Inc.","symbol":"ALEC"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-12T22:05:05.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":28700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 11, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":69950,"source":{"system":"sec-edgar","filing":"0000950170-25-085615","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213895/000095017025085615/ownership.xml","form_type":"4"}},{"id":1149293,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-05-14T21:07:36.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":7614,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":81352,"source":{"system":"sec-edgar","filing":"0001802768-25-000049","document":"wk-form4_1747256848.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000049/wk-form4_1747256848.xml","form_type":"4"}},{"id":1485052,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-06-10T20:11:08.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":9293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":73738,"source":{"system":"sec-edgar","filing":"0001802768-24-000027","document":"wk-form4_1718050260.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000027/wk-form4_1718050260.xml","form_type":"4"}},{"id":1564651,"issuer":{"id":6051,"kind":"organization","name":"Alector, Inc.","symbol":"ALEC"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-21T21:01:08.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":19420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the option vest in 48 equal monthly installments beginning on April 19, 2024."}],"balance_after":19420,"derivative":{"exercise_price":6.2,"expiration_date":"2034-03-19","underlying":"Common Stock","underlying_shares":19420},"source":{"system":"sec-edgar","filing":"0000950170-24-034848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1213895/000095017024034848/ownership.xml","form_type":"4"}},{"id":1564650,"issuer":{"id":6051,"kind":"organization","name":"Alector, Inc.","symbol":"ALEC"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-21T21:01:08.000Z","date":"2024-03-19","kind":"grant","planned":false,"acquired":true,"shares":41250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on September 1, 2024."}],"balance_after":41250,"source":{"system":"sec-edgar","filing":"0000950170-24-034848","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213895/000095017024034848/ownership.xml","form_type":"4"}},{"id":1723574,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-04T21:05:07.000Z","date":"2023-11-30","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person was granted 30,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 3,750 of these shares vest immediately and the remaining 26,250 shares vest ratably over a 42-month period, provided that the Reporting Person remains as Chair of the Board of Directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000950170-23-067736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1213895/000095017023067736/ownership.xml","form_type":"4"}},{"id":1723573,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-04T21:05:07.000Z","date":"2023-11-30","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0000950170-23-067736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213895/000095017023067736/ownership.xml","form_type":"4"}},{"id":1844284,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-06-26T20:04:11.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":7747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":64445,"source":{"system":"sec-edgar","filing":"0001209191-23-039672","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123039672/doc4.xml","form_type":"4"}},{"id":2222133,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-06-24T20:55:13.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":6328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":56698,"source":{"system":"sec-edgar","filing":"0000899243-22-024038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924322024038/doc4.xml","form_type":"4"}},{"id":2229683,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T00:55:48.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date."}],"balance_after":20000,"derivative":{"exercise_price":0.53,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001140361-22-023329","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213895/000114036122023329/form4.xml","form_type":"4"}},{"id":2549691,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-05T20:32:07.000Z","date":"2021-10-01","kind":"grant","acquired":true,"shares":3588,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of fees."}],"balance_after":29801,"source":{"system":"sec-edgar","filing":"0001209191-21-059424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121059424/doc4.xml","form_type":"4"}},{"id":2645474,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T13:51:33.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option will vest and become exercisable on June 9, 2022, the one-year anniversary of the grant date."}],"balance_after":14000,"derivative":{"exercise_price":4.55,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-21-044688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121044688/doc4.xml","form_type":"4"}},{"id":2645473,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T13:51:33.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":3406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of fees."}],"balance_after":26213,"source":{"system":"sec-edgar","filing":"0001209191-21-044688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121044688/doc4.xml","form_type":"4"}},{"id":2651972,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2021-06-30T00:34:32.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":5726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":50370,"source":{"system":"sec-edgar","filing":"0000950103-21-009693","document":"dp153554_4-desouza.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321009693/dp153554_4-desouza.xml","form_type":"4"}},{"id":2653184,"issuer":{"id":7698,"kind":"organization","name":"Korsana Biosciences, Inc.","symbol":"KRSA"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T21:08:09.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date."}],"balance_after":10000,"derivative":{"exercise_price":3.97,"expiration_date":"2031-06-24","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-21-022547","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213895/000114036121022547/form4.xml","form_type":"4"}},{"id":2758532,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T17:37:14.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":2926,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of fees."}],"balance_after":22807,"source":{"system":"sec-edgar","filing":"0001209191-21-025028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121025028/doc4.xml","form_type":"4"}},{"id":2916331,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-06T21:47:22.000Z","date":"2021-01-05","kind":"grant","acquired":true,"shares":2129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of fees."}],"balance_after":19881,"source":{"system":"sec-edgar","filing":"0001209191-21-002150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121002150/doc4.xml","form_type":"4"}},{"id":3016732,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-02T20:17:13.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of fees."}],"balance_after":17752,"source":{"system":"sec-edgar","filing":"0001209191-20-053117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919120053117/doc4.xml","form_type":"4"}},{"id":3023877,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2020-09-24T00:28:24.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":53915,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Errol Bento De Souza Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. (\"Holdings\") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI International Holdings 2019, LP (\"RPI Intl. LP\") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes RPI US LP Interests convertible into 39,010 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":53915,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":539150},"source":{"system":"sec-edgar","filing":"0000950103-20-018598","document":"dp137241_4-desouza.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320018598/dp137241_4-desouza.xml","form_type":"4"}},{"id":3023876,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2020-09-24T00:28:24.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":8929,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":44644,"source":{"system":"sec-edgar","filing":"0000950103-20-018598","document":"dp137241_4-desouza.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320018598/dp137241_4-desouza.xml","form_type":"4"}},{"id":3092609,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-02T20:41:22.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":2129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of fees."}],"balance_after":14627,"source":{"system":"sec-edgar","filing":"0001209191-20-040377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919120040377/doc4.xml","form_type":"4"}},{"id":3107378,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2020-06-18T01:49:24.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":35715,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35715,"source":{"system":"sec-edgar","filing":"0000950103-20-011924","document":"dp130580_4-desouza.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320011924/dp130580_4-desouza.xml","form_type":"4"}},{"id":3112134,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-12T20:44:35.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest monthly over a period of 12 months commencing June 11, 2020."}],"balance_after":5000,"derivative":{"exercise_price":7.18,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-036311","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919120036311/doc4.xml","form_type":"4"}},{"id":3183958,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-03T20:37:56.000Z","date":"2020-04-01","kind":"grant","acquired":true,"shares":2860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of fees."}],"balance_after":12498,"source":{"system":"sec-edgar","filing":"0001209191-20-023174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919120023174/doc4.xml","form_type":"4"}},{"id":3327524,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-02T21:44:20.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":1835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of stock received in lieu of fees."}],"balance_after":9638,"source":{"system":"sec-edgar","filing":"0001209191-20-000334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919120000334/doc4.xml","form_type":"4"}},{"id":3401372,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-02T20:06:47.000Z","date":"2019-10-01","kind":"grant","acquired":true,"shares":2545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of stock received in lieu of fees."}],"balance_after":7803,"source":{"system":"sec-edgar","filing":"0001209191-19-051609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119051609/doc4.xml","form_type":"4"}},{"id":3471787,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-02T20:33:24.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":1810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of stock received in lieu of fees."}],"balance_after":5258,"source":{"system":"sec-edgar","filing":"0001209191-19-040314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119040314/doc4.xml","form_type":"4"}},{"id":3488281,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-18T01:08:10.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest monthly over a period of 12 months commencing June 13, 2019."}],"balance_after":5000,"derivative":{"exercise_price":7.46,"exercise_date":"2020-06-13","expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-19-037567","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119037567/doc4.xml","form_type":"4"}},{"id":3569350,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T20:36:30.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":1504,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of stock received in lieu of fees."}],"balance_after":3448,"source":{"system":"sec-edgar","filing":"0001209191-19-022525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119022525/doc4.xml","form_type":"4"}},{"id":3709615,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-03T22:43:47.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":1703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of stock received in lieu of fees."}],"balance_after":1944,"source":{"system":"sec-edgar","filing":"0001209191-19-001218","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119001218/doc4.xml","form_type":"4"}},{"id":3892771,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-15T21:52:08.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest monthly over a period of 12 months commencing June 13, 2018."}],"balance_after":5000,"derivative":{"exercise_price":24.94,"exercise_date":"2019-06-13","expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-18-038134","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919118038134/doc4.xml","form_type":"4"}},{"id":4040962,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Redeemable Convertible Note","published_at":"2018-02-22T21:30:33.000Z","date":"2018-02-20","kind":"other","acquired":false,"shares":4679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1:15 reverse stock split effected on February 10, 2017."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects a redeemable convertible note of the Issuer (the \"Note\") that matured, with the face value of the Note repaid to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the option of the Reporting Person, at any time on or before February 19, 2018, the Note was redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Note matured on February 19, 2018."}],"balance_after":0,"derivative":{"exercise_price":137.85,"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001209191-18-012430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919118012430/doc4.xml","form_type":"4"}},{"id":4040961,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Redeemable Convertible Note","published_at":"2018-02-22T21:30:33.000Z","date":"2018-02-20","kind":"other","acquired":false,"price":0,"reported_value":10800,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1:15 reverse stock split effected on February 10, 2017."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects a redeemable convertible note of the Issuer (the \"Note\") that matured, with the face value of the Note repaid to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the option of the Reporting Person, at any time on or before February 19, 2018, the Note was redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Note matured on February 19, 2018."}],"derivative":{"exercise_price":137.85,"underlying":"Common Stock","underlying_shares":78},"source":{"system":"sec-edgar","filing":"0001209191-18-012430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919118012430/doc4.xml","form_type":"4"}},{"id":4257237,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":37182,"kind":"person","name":"DESOUZA ERROL B","position":1,"cik":"0001213895","reported_name":"DESOUZA ERROL B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-14T20:51:51.000Z","date":"2017-07-13","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest monthly over a period of 12 months commencing June 15, 2017."}],"balance_after":10000,"derivative":{"exercise_price":4.4,"exercise_date":"2018-06-15","expiration_date":"2027-07-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-045212","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919117045212/doc4.xml","form_type":"4"}}]}